Article

Pharmaceutical Executive

Pharmaceutical Executive

Pharmaceutical Executive-09-01-2004
Volume

September Table of Contents

September Table of Contents

External Link - article-124696.pdf

Articles in this issue
September Table of Contents
i2-122706-1408706455037.gif
(Huge) Untapped Opportunity
Information Into Action
Information Into Action
main-123005-1408706833113.jpg
Halting the Hype
i4-123004-1408706836594.jpg
Spend Trends: A $20 Billion Bill and Plenty of Change
September Table of Contents

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Related Content
Gilead Subsidiary Kite to Acquire Interius BioTherapeutics for $350 Million
August 23rd 2025

Gilead Subsidiary Kite to Acquire Interius BioTherapeutics for $350 Million

Don Tracy, Associate Editor
The Rx for High-Performance Leadership: Cutting Through the Chaos
August 23rd 2025

The Rx for High-Performance Leadership: Cutting Through the Chaos

Michael Christel
Stock.adobe.com
August 23rd 2025

Lighthouse Pharmaceuticals Awarded $49.2 Million Grant from NIA to Advance Phase 2 study of LHP588

Nicholas Jacobus
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
August 23rd 2025

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
© WESTOCK - © WESTOCK - stock.adobe.com
August 23rd 2025

Supreme Court Upholds NIH Funding Cuts Affecting DEI in Clinical Research

Andy Studna
XOMA Royalty Subsidiary to Acquire Mural Oncology in Premium Cash Transaction
August 23rd 2025

XOMA Royalty Subsidiary to Acquire Mural Oncology in Premium Cash Transaction

Don Tracy, Associate Editor